COPD — SCE Respiratory MCQ

Correct answer: A — Dual bronchodilator LABA/LAMA

The correct answer is A, dual bronchodilator LABA/LAMA. NICE NG115 stratifies escalation of COPD pharmacotherapy according to the presence or absence of asthmatic features or steroid responsiveness (history of asthma or atopy, higher FEV1 variability, or blood eosinophils raised, generally taken as 0.3x10^9/L or above). This patient has an eosinophil count of 120/uL (0.12x10^9/L), well below that threshold, and no other asthmatic features are described, despite having frequent exacerbations and mMRC 2 breathlessness on no maintenance therapy. In this scenario NICE recommends offering LABA plus LAMA dual bronchodilation as the next step up from short-acting therapy, reserving ICS-containing regimens for those with steroid-responsive features or eosinophilia. Dual bronchodilation improves airflow, symptoms and reduces exacerbation frequency without the pneumonia risk associated with unnecessary inhaled corticosteroid use in a low-eosinophil phenotype. Why the other options are wrong: C. LABA monotherapy: Long-acting bronchodilator monotherapy is no longer recommended as an escalation step once symptoms or exacerbations persist; LAMA/LABA combination gives greater bronchodilation and exacerbation reduction than either agent alone. E. ICS/LABA: ICS-containing regimens are reserved for patients with asthmatic features or blood eosinophils around 0.3x10^9/L or higher; using ICS here exposes the patient to unnecessary pneumonia risk without proven added benefit given the low eosinophil count. D. Roflumilast: This is an add-on option for severe COPD with chronic bronchitis and continued exacerbations despite triple inhaled therapy, not an initial agent. B. Azithromycin prophylaxis: Long-term macrolide prophylaxis is considered only after optimisation of inhaled therapy, smoking cessation and pulmonary rehabilitation have failed to control exacerbations, and after excluding contraindications such as QT prolongation. Key point: In UK practice (NICE NG115), escalate to LABA/LAMA dual bronchodilation for exacerbating or symptomatic COPD without asthmatic features or eosinophilia, reserving ICS-containing regimens for eosinophils around 0.3x10^9/L or higher.

Reference: NICE Guideline NG115, Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2018, updated 2019), section 1.2: pharmacological management, treatment algorithm for people without asthmatic features/steroid responsiveness. https://www.nice.org.uk/guidance/ng115